164 related articles for article (PubMed ID: 16489036)
1. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
Friedman A; Tian JP; Fulci G; Chiocca EA; Wang J
Cancer Res; 2006 Feb; 66(4):2314-9. PubMed ID: 16489036
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
Kambara H; Saeki Y; Chiocca EA
Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
[TBL] [Abstract][Full Text] [Related]
3. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.
Ikeda K; Ichikawa T; Wakimoto H; Silver JS; Deisboeck TS; Finkelstein D; Harsh GR; Louis DN; Bartus RT; Hochberg FH; Chiocca EA
Nat Med; 1999 Aug; 5(8):881-7. PubMed ID: 10426310
[TBL] [Abstract][Full Text] [Related]
6. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
Li H; Zeng Z; Fu X; Zhang X
Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791
[TBL] [Abstract][Full Text] [Related]
8. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
10. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
[TBL] [Abstract][Full Text] [Related]
11. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
12. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
13. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
Tyminski E; Leroy S; Terada K; Finkelstein DM; Hyatt JL; Danks MK; Potter PM; Saeki Y; Chiocca EA
Cancer Res; 2005 Aug; 65(15):6850-7. PubMed ID: 16061668
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
15. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
Fulci G; Breymann L; Gianni D; Kurozomi K; Rhee SS; Yu J; Kaur B; Louis DN; Weissleder R; Caligiuri MA; Chiocca EA
Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12873-8. PubMed ID: 16908838
[TBL] [Abstract][Full Text] [Related]
17. [Brain tumor therapy using replication--competent virus vectors].
Todo T
Nihon Rinsho; 2005 Sep; 63 Suppl 9():504-9. PubMed ID: 16201572
[No Abstract] [Full Text] [Related]
18. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
[TBL] [Abstract][Full Text] [Related]
19. HSV1716 persistence in primary human glioma cells in vitro.
Harland J; Papanastassiou V; Brown SM
Gene Ther; 2002 Sep; 9(17):1194-8. PubMed ID: 12170384
[TBL] [Abstract][Full Text] [Related]
20. Varicella zoster virus infection of malignant glioma cell cultures: a new candidate for oncolytic virotherapy?
Leske H; Haase R; Restle F; Schichor C; Albrecht V; Vizoso Pinto MG; Tonn JC; Baiker A; Thon N
Anticancer Res; 2012 Apr; 32(4):1137-44. PubMed ID: 22493342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
